)

Bio-Rad Laboratories (BIO) investor relations material
Bio-Rad Laboratories Wells Fargo 20th Annual Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Financial and operational highlights
Q2 saw strong revenue, driven by process chromatography and consumables, with operating margin improvement due to tariff stabilization and tight expense management.
Free cash flow was robust, and the Stillia acquisition was completed, with positive customer feedback and pipeline growth.
The company raised its full-year guide for process chromatography, expecting low double-digit growth, and sees improved visibility and stability in this segment.
Diagnostics ex-China grew 3.7% in Q2, with Quality Systems as a key contributor; China remains a headwind due to reimbursement changes.
Tariff headwinds have been largely mitigated, with only a 30–40 basis point impact expected for the rest of the year.
Market and segment trends
Biopharma instrument demand remains soft, especially among smaller players, while consumables show steady activity; large pharma has stabilized.
Academic and government (A&G) markets in the US are stable but cautious, awaiting NIH budget clarity; Europe faces pressure from budget shifts, and China remains challenged.
ddPCR portfolio expansion, including the launch of Continuum, is expected to drive mid single-digit growth in the near term, with long-term goals of high single-digit to double-digit growth.
Adoption of digital PCR in diagnostics is in early stages, with growth opportunities in oncology and rare event detection.
The Stillia acquisition is expected to reach accretion within 18–24 months, with ongoing updates based on market uptake.
Strategic initiatives and outlook
Supply chain improvements, including lean manufacturing and logistics consolidation, have increased productivity and capacity, especially in Singapore.
Working capital efficiency is a focus, with initiatives to improve inventory turns and procurement leverage, aiming for better free cash flow.
Q4 revenue ramp is expected, driven by Quality Systems lot releases and ddPCR portfolio sales; 4–5% organic growth is anticipated for Q4, but 2026 guidance remains cautious.
Margin expansion requires at least 3% top-line growth, with SG&A leverage targeted through productivity and expense management.
Capital allocation priorities include reinvestment in the business, strategic acquisitions, and opportunistic share repurchases.
Next Bio-Rad Laboratories earnings date

Next Bio-Rad Laboratories earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage